Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients | ||
By: PR Newswire Association LLC. - 23 Apr 2024 | Back to overview list |
|
New Research Highlights SOMAVEDIC's Potential in Enhancing Vision Health for the Opthalmology Unit Hospital Patients SAN FRANCISCO, April 23, 2024 /PRNewswire/ -- Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with researchers from the Eye Clinic of Jan Evangelista Purkyn? University and Masaryk Hospital in Ústí nad Labem in the Czech Republic, have unveiled groundbreaking findings from a study showcasing the effectiveness of the Somavedic device in supporting individuals with wet age-related macular degeneration (wet AMD), a prevalent cause of severe vision impairment among older adults. Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients The study enrolled patients with newly diagnosed wet AMD and active choroidal neovascularization (CNV), where anti-VEGF therapy was indicated. Parameters including best corrected visual acuity (BCVA), central macular thickness (CRT), macular volume (TMV), and OCT angiography were monitored. Patients received a functioning Somavedic device for home use, while the other group was administered a non-functional placebo device. After one month, results from 18 completed patient cases revealed significant findings. Patients using the functional Somavedic device (group A) experienced a mean improvement of +4.2 ETDRS letters in BCVA, accompanied by a reduction of -7.6 ?m in CRT and -0.232 mm3 in TMV. Conversely, patients in the control group (group B) showed minimal changes in BCVA (+0 letters), with an increase of +75 ?m in CRT and +0.757 mm3 in TMV. Dr. Martina Závorková, PhD the lead researcher of the study, expressed enthusiasm regarding the results, stating, "Our findings suggest that Somavedic may play an important role in slowing the progression of age-related macular degeneration and offer a promising, non-invasive adjunctive approach to managing wet AMD. Further exploration is necessary to elucidate its mechanism of action and long-term benefits." "We are immensely encouraged by the positive outcomes of this study, which underscore the potential of Somavedic to make a meaningful impact on the lives of individuals affected by wet age-related macular degeneration. This research reaffirms our commitment to advancing innovative solutions that promote better vision health and overall well-being," said Juraj Kocar, CEO of Somavedic Technologies. The positive outcomes of this study pave the way for larger-scale clinical trials to substantiate the efficacy of Somavedic in wet AMD management. If validated, this innovative technology has the potential to revolutionize treatment strategies and significantly enhance the quality of life for individuals affected by this debilitating eye condition. About SOMAVEDIC: Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/breakthrough-study-reveals-somavedic-devices-potential-impact-on-wet-amd-patients-302124621.html SOURCE Somavedic Technologies Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |